Quick Answer
Seres Therapeutics, Inc. reported Total Revenue of $789.0 thousand for fiscal year 2025.
Seres Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $789.0K | $0.00 | $0.00 -100.0% |
$7.13M -95.1% |
$144.93M +336.3% |
$33.22M -3.7% |
| Revenue (ASC 606) | — | — | — | $7.13M -95.0% |
$143.86M +1109.2% |
$11.90M -56.2% |
| Net Income | $5.70M +4088.2% |
$136.0K +100.1% |
-$113.72M +54.5% |
-$250.16M -281.5% |
-$65.58M +26.4% |
-$89.13M -26.8% |
| Diluted EPS | $0.64 | $0.00 +100.0% |
-$17.77 -669.3% |
-$2.31 -220.8% |
-$0.72 +35.7% |
-$1.12 |
| Total Assets | $138.19M -1.2% |
$139.81M -61.0% |
$358.60M +2.8% |
$348.78M -1.7% |
$354.86M +3.5% |
$342.94M +158.9% |
| Cash and Equivalents | $45.77M +48.6% |
$30.79M -75.9% |
$127.97M -21.5% |
$163.03M -9.4% |
$180.00M +55.1% |
$116.05M +78.2% |
| Stockholders Equity | $44.22M +220.8% |
$13.78M +130.7% |
-$44.86M -516.0% |
$10.78M -91.8% |
$131.51M -24.7% |
$174.75M +461.6% |
| R&D Expense | $49.06M -24.1% |
$64.60M -45.1% |
$117.60M +7.2% |
$109.65M -22.7% |
$141.89M +56.7% |
$90.57M +13.0% |
| Operating Income | -$93.97M +22.5% |
-$121.31M +37.8% |
-$195.10M -8.4% |
-$179.91M -179.0% |
-$64.49M +26.8% |
-$88.13M -22.6% |
| Shares Outstanding | 9.56M +10.5% |
8.65M -93.6% |
135.04M +7.8% |
125.22M +36.3% |
91.89M +0.5% |
91.46M +30.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $351.0K | — | — |
| Revenue (ASC 606) | September 30, 2022 | $3.44M | -97.3% | +183.2% |
| Net Income | September 30, 2025 | $8.20M | -90.8% | +141.3% |
| Diluted EPS | September 30, 2025 | $0.94 | -91.9% | +141.4% |
| Total Assets | September 30, 2025 | $143.47M | -19.7% | -0.2% |
| Cash and Equivalents | September 30, 2025 | $47.64M | -28.7% | +5.0% |
| Stockholders Equity | September 30, 2025 | $43.70M | +82.7% | +32.6% |
| R&D Expense | September 30, 2025 | $12.62M | -23.4% | -2.5% |
| Operating Income | September 30, 2025 | -$22.48M | +22.9% | +9.7% |
| Shares Outstanding | September 30, 2025 | 8.76M | -94.9% | +0.1% |
- Seres Therapeutics, Inc. reported Total Revenue of $789.0 thousand for fiscal year 2025.
- Seres Therapeutics, Inc. reported Revenue (ASC 606) of $7.13 million for fiscal year 2022.
- Seres Therapeutics, Inc. showed a decrease of -95.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Net Income of $5.70 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed an increase of +4088.2% in Net Income compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Diluted EPS of $0.64 per share for fiscal year 2025.
- Seres Therapeutics, Inc. reported Total Assets of $138.19 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed a decrease of -1.2% in Total Assets compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Cash and Equivalents of $45.77 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed an increase of +48.6% in Cash and Equivalents compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Stockholders Equity of $44.22 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed an increase of +220.8% in Stockholders Equity compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported R&D Expense of $49.06 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed a decrease of -24.1% in R&D Expense compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Operating Income of -$93.97 million for fiscal year 2025.
- Seres Therapeutics, Inc. showed an increase of +22.5% in Operating Income compared to the prior fiscal year.
- Seres Therapeutics, Inc. reported Shares Outstanding of 9.56 million shares for fiscal year 2025.
- Seres Therapeutics, Inc. showed an increase of +10.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: